Autologous Stem Cell Transplant With Pomalidomide (CC-4047) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium

Trial Profile

Autologous Stem Cell Transplant With Pomalidomide (CC-4047) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Pomalidomide (Primary) ; Clarithromycin; Dexamethasone; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 30 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
    • 30 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top